KR101064848B1 - Extracts of Mimosa pudica for allergy treating and pharmaceutical compositions for allergy comprising the extracts - Google Patents

Abstract

The present invention relates to a mimosa extract and a pharmaceutical composition for treating allergies comprising the same as an active ingredient, in order to confirm the usefulness of the extract of the mimosa (1) extracts of mimosa for jujutsu movement of mast cells by stem cell factor Effect, (2) toxic effect of mimosa extract on cells, (3) inflammatory cytokines and chemokines, MCP-1 (monocyte chemoattractant protein-1) and IL-6 in human eosinophilic leukemic cells The inhibitory effect of mimosa extract on (Interleukin-6) and (4) the effects of mimosa extract on asthma-induced mice were confirmed, and it can be confirmed that it can be effectively used for improving or treating atopy and / or asma. there was.

Atopy, Asma, Mimosa, Chemokine, Interleukin, Mast Cell

Description

Extracts of mimosa for allergy and pharmaceutical compositions for allergy comprising the same as active ingredients {Extracts of Mimosa pudica for allergy treating and pharmaceutical compositions for allergy comprising the extracts}

The present invention relates to a mimosa extract and a pharmaceutical composition for treating allergies comprising the same as an active ingredient, in particular, the present invention relates to mimosa extract having an alleviating and / or therapeutic effect on an allergic disease such as atopy or asma, and the same as an active ingredient. It relates to a pharmaceutical composition for treating allergy.

Atopy (atopy) is a skin disease that has been used since Coca in 1925 described atopic dermatitis, asthma and fever as a result of allergic reactions to food and inhalable substances. In addition to atopic dermatitis, there are asthma, allergic rhinitis, and allergic conjunctivitis. Atopic dermatitis is accompanied by allergic reactions. Among them, atopic dermatitis is chronic or recurrent dermatitis, which has a characteristic shape and distribution of skin lesions and atopic history of an individual or family. It is a very common skin disease that occurs. Atopic dermatitis usually begins around zero, infancy, and especially around two months of age, of which about 50% occurs before 2 years of age, and symptoms rarely occur before about 5 years of age, while in adults only very few cases appear first. . In most cases, with symptoms, the symptoms are alleviated or disappeared, and more than half of the infants develop before 2 years of age.

Atopic dermatitis begins with erythematous papules and seizures with severe itching and progresses to acute symptoms with blisters and serous exudates and crusts. The most characteristic symptom is pruritus, which is so severe that it bleeds to bleeding, and it continues to worsen with a vicious cycle of itching-scratching-itching. Most clinical manifestations are caused by scratching or rubbing, and at night, pruritus becomes more severe and causes sleep disorders. In recent years, the incidence of atopic dermatitis has been increasing worldwide, which may be attributed to air pollution, changes in the residential environment, increased exposure to antigens, reduced breastfeeding, and reduced childhood disease. have. According to a national epidemiological study conducted by the Korean Academy of Pediatric Allergy and Respiratory Diseases in 1995, 12 to 24% of elementary school students and 6 to 8% of middle school students were diagnosed with atopic dermatitis.In 2000, 24.9% of elementary school students and In addition to 12.8% diagnosed atopic dermatitis, adult atopic dermatitis is also increasing in Korea.

The exact pathophysiology of the atopic dermatitis is not yet fully understood, but it is thought that immunological and non-immunological mechanisms are involved with genetic predisposition. Exogenous atopic dermatitis, which accounts for the majority of atopic dermatitis, is caused by an immune mechanism associated with immunoglobulin E (IgE), and many reports indicate that the primary immune response is caused by T-cell abnormalities rather than a secondary immune response to a particular allergen. As cell-mediated immune dysfunction is associated with an increase in immunoglobulin E in patients with atopic dermatitis, there are increasing reports claiming that the primary immune response is involved in the pathogenesis of atopic dermatitis in addition to the secondary immune response (Kee Young, et al. , Korean Medicine, Seoul, 2001, pp23 ~ 52).

It is known that cell-mediated immune disorders occur in patients with atopic dermatitis up to about 80%, and the susceptibility to skin infections caused by viruses and skin filaments is increased, and the sensitivity to contact allergens tends to decrease. In the past, T-cell maturation deficiency and the decrease in the number of CD8 + inhibitory T-cells have been reported. Recently, the role of CD4 + T-cells is known to be more important. That is, T-cells secreting interleukin 4, 5 that induces or promotes the production of immunoglobulin E from B cells, and interleukin 6 that amplify are Th2 cells among CD4 + T-cells, which are Th1 cells in the skin of atopic patients. It was found that Th2 cells were present higher than that of the cells. These cytokines stimulate immune cells such as mast cells, macrophages and basophils to promote secretion of histamine, leukotrien, prostaglandin and nitric oxide (NO). These inflammatory mediators are known to promote skin inflammatory responses. These cytokines are proteins that cells secrete out of cells in certain situations, mainly known for their interleukin (IL) family, and the role of interleukins varies greatly between individual interleukins, and some may play a part in immune function. Some of them induce differentiation of other cells.

Another characteristic of atopic dermatitis is the lack of gamma-linolenic acid in lipids that form the cell membranes of skin cells. Gamma linolenic acid deficiency is a phenomenon caused by impaired synthesis of linoleic acid to gamma linolenic acid due to a loss of function of delta-6-desaturase in the biosynthetic pathway of essential fatty acids, followed by prostaglandins Do not control the synthesis of the back, the production of inflammatory mediators will increase. In addition, the deficiency of gamma linolenic acid causes abnormalities in the structure of the skin lipid membrane, resulting in excessive water leakage, resulting in the breakdown of the skin barrier, and at this time, secondary infection such as bacteria occurs.

Meanwhile, in other studies on atopy, the occurrence of atopic dermatitis by chemokines has also been reported. These chemokines are also the same as the cytokines described above in terms of proteins expressed in cells, but the action is known to be slightly different. That is, the chemokines mainly serve to attract specific cells to a specific site. That is, when a cell expresses a specific chemokine, cells of the kind that respond to the chemokine move toward the cell where the chemokine is expressed, and it is known that it serves as a kind of aggregation signal. In particular, it is a type of cytokine that regulates the movement and activation of various types of white blood cells, and controls the infiltration of inflammatory cells into tissues. Particularly known chemokines include CCL22 / MDC and CCL17 / TARC (recovery and triggering T-cells; T-cell production of interleukin 4, interleukin 5, interleukin 13 and TNF-α), TSLP (increased production of TARC and MDC) Resulting dendritic cells activation), CCL27 / CTACK (recovery and migration of lymphocytes) and RANTES (eosinophils and T-cell migration / activation; increased eosinophil adhesion to endothelial cell surface). Here MDC stands for macrophage-derived chemokine and TARC stands for thymus and activation-regulated chemokine, which can also be produced in keratinocytes. Overproduction of TARC contributes to significant infiltration of TH2 T cells into atopic lesion skin, TSLP stands for thymic stromal lymphopoietin and CTACK stands for cutaneous T-cell-induced chemokine -cell-attracting chemokine, and RANTES means regulated on activation, normal T cells expressed and secreted.

Figure 1 is a schematic diagram showing the process of causing atopic dermatitis and asma histological lesions. In addition, Fig. 2 shows a schematic diagram illustrating the interaction between cytokines and chemokines that cause atopic dermatitis and asma.

In view of the etiology, mechanisms, and symptoms of atopic dermatitis as described above, a therapeutic agent for atopic dermatitis has been developed. As a result, a number of natural or synthetic immunosuppressive agents, antihistamines, steroid preparations, and the like have been developed. For example, immunosuppressants include Cyclosporin A, FK506 (Tacrolimus, Tacrolimus; Wasik et al., Immunopharmacology 20: 57-61, 1990) and SDZ ASM981 (Pimecrolimus, Pimecrolimus; Grassberger et al., Br. J. Dermatology 141: 264-273, 1999). On the other hand, steroids and antihistamines, which are used as treatments for atopic dermatitis, have the effect of temporarily relieving symptoms, but skin thinning and osteoporosis in long-term use of external or oral steroid hormones. It is clinically problematic due to local and systemic side effects such as induction and growth inhibition in children. Therefore, there is a need to develop a therapeutic agent having no such side effects and excellent efficacy.

Mimosa is a plant belonging to the genus Soybean Dicotyledon bean and Mimosa genus. Its scientific name is Mimosa pudica (Mp), and it is a perennial plant native to Brazil. It is about 30㎝ high and gives a physical stimulus to the leaf or moves according to the change of light. In oriental medicine, the rest of the root is used as a drug called hyacinth, and it is known to have an effect on obscurity caused by enteritis, gastritis, and nervous breakdown.

On the other hand, the present inventors (1) the effect of the extract of mimosa on the migrating movement of mast cells by stem cell factor involved in atopic dermatitis and asma, (2) the toxic effect on the cells of mimosa extract, (3) EoL- Inhibitory Effect of Mimosa Extracts on Inflammatory Cytokines and Chemokines of MCP-1 and IL-6 (Interleukin-6) in Human Eosinophilic Leukemic Cells and (4) Asthma-Induced Mice The effects of mimosa extracts on were identified and the present invention was completed.

In view of the above, the inventors of the present invention, while conducting research on natural products that can treat allergic diseases such as atopic dermatitis and asma, are known as extracts of mimosa caused by stem cell factors (Human Mast Cell; HMC-1). The inhibitory effect on the exercise of jujube, the inhibitory effect of the production of inflammatory cytokines and chemokines MCP-1, interleukin-6 in EoL-1 cells were confirmed, and tested for cytotoxicity to prepare a non-toxic or low-toxic pharmaceutical composition It was confirmed whether or not, and extracting the extract of the mimosa in asthma disease-inducing mice to check the effects of the pharmaceutical composition containing the extract of the mimosa as an active ingredient useful for atopic diseases and asma (asthma) diseases, etc. The present invention has been completed by confirming that it can be used.

The present invention provides an extract of mimosa for improving or treating skin diseases and asma.

The extract of mimosa may be selected from the group consisting of ethanol extract, hexane fraction of the ethanol extract, ethyl acetate fraction of ethanol extract, butanol fraction of ethanol extract and water fraction of ethanol extract.

The present invention also provides a pharmaceutical composition for improving or treating skin diseases and asma including the extract of mimosa as an active ingredient.

The skin disease may be selected from the group consisting of atopic dermatitis, acne, general dermatitis, athlete's foot.

Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings.

The present invention provides an extract of mimosa for improving or treating skin diseases and asma. The extract of mimosa refers to a liquid portion obtained by dipping and solid-liquid separation of dried mimosa outpost (including whole leaves, stems and roots) with an extraction solvent according to a conventional extraction method. In the above extraction method, the dried mimosa starch is added to ethanol (80% concentration) in an amount ranging from 500 to 1,500 mL with respect to 100 g of mimosa starch, and three times the ethanol immersion extraction is allowed to stand at room temperature for 20 to 30 hours. After collecting the immersion extracts repeatedly, the impurities are filtered to remove impurities, and the ethanol extract of mimosa according to the present invention can be prepared by concentrating to a volume of 1/2 to 1/4 of the total amount of immersion extract, The invention is not limited thereto, and it is easily understood by those skilled in the art that the concentration and amount of ethanol used, the immersion temperature and immersion time, the number of repetition of immersion extraction, the degree of filtration and concentration of the immersion extract may be changed as appropriate. It can be. In addition, it is to be understood that other known extraction methods, for example, supercritical extraction using liquid carbon dioxide or methods such as room temperature immersion extraction without heating, may be used.

The mimosa ethanol extract may be further fractionated into hexane fraction, ethyl acetate fraction, butanol fraction and water fraction.

The hexane fraction is a liquid separation process of suspending the ethanol extract of mimosa in water, adding the same amount of n-hexane, shaking, and then leaving the upper layer of hexane to separate the upper layer of the hexane extract. Repeating three times, and after collecting the fractions, the hexane fraction of mimosa of the present invention can be prepared by concentrating to a volume of 1/2 to 1/4 of the total amount of the fractions.

The ethyl acetate fraction was obtained from the ethanol extract of mimosa as described above, and then obtained with hexane fraction, and then the same amount of ethyl acetate was added using acetonitrile instead of hexane using the remaining aqueous layers, followed by shaking. When the mixture is separated into an upper layer composed of ethyl acetate and an aqueous layer below, the separation process of separating only the upper layer is repeated three times, and after collecting the fractions, the volume of 1/2 to 1/4 of the total amount of the fractions The ethyl acetate fraction of mimosa of the present invention can be prepared by concentrating as much as possible.

The butanol fraction is obtained from the ethanol extract of mimosa as described above, and then ethyl acetate fraction is added, using butanol instead of ethyl acetate using the remaining aqueous layers, the same amount of butanol is added as above, followed by shaking. When separated into the upper layer consisting of butanol and the water layer below it is repeated three times the separation process of separating only the upper layer, and after collecting the fractions, concentrated to a volume of 1/2 to 1/4 of the total amount of the fractions The butanol fraction of mimosa according to the present invention can be prepared.

The water fraction is obtained by obtaining the butanol fraction as described above from the ethanol extract of mimosa, collecting the remaining aqueous layers, and concentrating to a volume of 1/2 to 1/4 of the total amount of the aqueous layers. The water fraction of mimosa according to the invention can be prepared.

Preparation of each fraction of mimosa according to the present invention as described above is not limited to the embodiments described above, the concentration and amount of hexane, ethyl acetate, butanol used, the number of times of shaking and separation and the degree of concentration, etc. It can be easily understood by those skilled in the art that both can be changed.

In order to confirm the usefulness of the extract of the mimosa (1) the effect of the extract of mimosa on the migrating movement of mast cells by stem cell factor, (2) the toxic effect on the cells of mimosa extract, (3) EoL-1 cells Inhibitory Effect of Mimosa Extracts on Inflammatory Cytokines and Chemokines MCP-1 and IL-6 (Interleukin-6) in Human Eosinophilic Leukemic Cells and (4) on Asthma-Induced Mice The effects of mimosa extract were confirmed, and from these, it could be confirmed that it can be effectively used for the improvement or treatment of atopy and / or asma.

The present invention also provides a pharmaceutical composition for improving or treating skin diseases and asma including the extract of mimosa as an active ingredient.

The pharmaceutical composition may further include a pharmaceutically usable carrier or dispersant, suspending agent, stabilizer, and the like, and may be used as a raw material for cosmetics, bath products, soaps, pharmaceutical ointments, animal medicines, or pack products.

The pharmaceutical composition may be parenterally administered during clinical administration, and may be used in the form of a general pharmaceutical formulation. That is, it may be prepared as a solution, suspension, spray, patch, pad, cream, ointment, gel, tablet or pill.

Solutions include, in addition to the active compounds, conventional excipients, for example solvents, solubilizers and emulsifiers, for example water, ethanol, isopropanol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl Lenglycol, dimethylformamide, oils, in particular cottonseed oil, peanut oil, camellia oil, aloe vera, glycerin, jade oil, olive oil, castor oil, almond oil and sesame oil, glycerol, glycerol form alcohol, tetrahydrofurfuryl alcohol, polyethylene glycol and Fatty acid esters of sorbitan, or mixtures of these materials, and may include methyl- or propyl-p-hydroxybenzoate, sorbic acid, and the like as preservatives.

Suspending agents, in addition to active compounds, include conventional excipients, for example liquid diluents such as water, ethanol and propylene glycol, polyethylene glycol, and suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, sorbitan esters, Cellulose derivatives and hydrogenated edible oils), microcrystalline cellulose, aluminum methoxide, bentonite, agar and tragacanth, injectable esters such as ethyl oleate or mixtures of these materials.

Ointments, creams and gels may be used in addition to the active compounds, as usual excipients, for example animal and vegetable fats, wax paraffins, starches, targacanths, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc and zinc oxide or these substances It may contain a mixture of.

In addition, the method of administration may be generally applied to the affected area, it is possible to select the preferred method of administration depending on the formulation. Daily dosage of the composition of the present invention may be determined depending on the administration target, administration method, symptoms. The number of administration is preferably two or more times a day, but the number of administration may also be adjusted according to the degree of symptoms. That is, the method of administration, dosage and frequency of administration may be changed in particular taking into account the constitution specificity and weight of the subject to be treated, the type and depth of the disease, the nature of the formulation, the nature of the drug administration, and the duration or interval of administration.

In order to effectively treat atopy, it is important to select a suitable external formulation. In order to treat atopy, mimosa extract may be appropriately diluted and applied directly to the skin, and the present invention provides an ointment which can be effectively applied to the affected area for treating the atopy. The ointment of the present invention is prepared by combining the pharmaceutical composition for treating atopy described above with an inorganic substance and then coating it with a fat-soluble base. The inorganic material is preferably used a material having excellent antibacterial, anti-inflammatory effect, epidermal regeneration effect, and specific examples thereof include zinc oxide, zinc carbonate, iron oxide.

In addition, it is preferable to further use a ceramic carrier capable of safely impregnating the composition for treating atopy of the present invention, which is a water-soluble substance. As the ceramic carrier, zeolite, talc, gypsum, seed powder and mixtures thereof are preferably used. Such a ceramic carrier is excellent in the impregnation of the water-soluble component can facilitate the supply of the water-soluble component to the skin.

The skin disease may be selected from the group consisting of atopic dermatitis, acne, general dermatitis, athlete's foot.

Therefore, according to the present invention, there is an effect of providing an extract of mimosa having alleviation and / or treatment effect for allergic diseases such as atopy or asma, and a pharmaceutical composition for treating allergy and asma including the same as an active ingredient.

Hereinafter, preferred embodiments and comparative examples of the present invention will be described.

The following examples are intended to illustrate the invention and should not be understood as limiting the scope of the invention.

Examples 1-5

The mimosa ethanol extract (Example 1) and each fraction (Examples 2 to 5) were prepared using the dried mimosa outpost.

100 g of dried mimosa starch (including the entire leaf, stem and root) was added to ethanol (80% concentration) in an amount in the range of 1,000 ml, and ethanol immersion extraction, which was left at room temperature for 24 hours, was repeated three times. The immersion extracts were collected, filtered to remove impurities, and concentrated to a volume of 1/3 of the total amount of the immersion extract to prepare an ethanol extract of mimosa (Example 1) according to the present invention.

The ethanol extract of Mimosa was further fractionated into hexane fraction, ethyl acetate fraction, butanol fraction and water fraction.

The hexane fraction is a liquid separation process of suspending the ethanol extract of mimosa in water, adding the same amount of n-hexane, shaking, and then leaving the upper layer of hexane to separate the upper layer of the hexane extract. Repeated three times, and after collecting the fractions, the hexane fraction of mimosa of the present invention (Example 2) can be prepared by concentrating to a volume of 1/3 of the total amount of the fractions.

The ethyl acetate fraction was obtained from the ethanol extract of mimosa as described above, and then obtained with hexane fraction, and then the same amount of ethyl acetate was added using acetonitrile instead of hexane using the remaining aqueous layers, followed by shaking. When the mixture is separated into an upper layer composed of ethyl acetate and an aqueous layer below, the separation process of separating only the upper layer is repeated three times, and the fractions are collected and concentrated to a volume of 1/3 of the total amount of the fractions. By this, ethyl acetate fraction of Mimosa according to the present invention (Example 3) can be prepared.

The butanol fraction is obtained from the ethanol extract of mimosa as described above, and then ethyl acetate fraction is added, using butanol instead of ethyl acetate using the remaining aqueous layers, the same amount of butanol is added as above, followed by shaking. When separated into the upper layer consisting of butanol and the water layer below it is repeated three times the separation process of separating only the upper layer, and after collecting the fractions, by concentrating to a volume of 1/3 of the total amount of the fractions Butanol fraction of mimosa according to the invention (Example 4) can be prepared.

The water fraction is obtained from the ethanol extract of mimosa as described above, butanol fractions are collected, the remaining aqueous layers are collected, and then concentrated to a volume equal to 1/3 of the total amount of the aqueous layers. The water fraction (Example 5) of can be manufactured.

Experimental Example 1

Inhibitory Effect of Mimosa Extracts on Mast Cell Migration

When the above examples were treated for 24 hours by treating 10 μg / ml with 5 * 10 ⁶ cells / ml of human mast cell line (HMC-1 cells), the number of mobile cells for the stem cell factor of 100 ng / ml was measured. It was. When the control group of the untreated state was set to 100%, it was shown in Figure 3 comparing the migration rate of the treated mast cells.

As shown in Figure 3, mimosa extracts can be confirmed that the mesokinetic movement of mast cells.

As a result of experiments on mast cells, one of the causative agents causing asthma, the extract of mimosa had the effect of inhibiting the migration of mast cells, and it was confirmed that there is a possibility of therapeutic effect against allergic diseases.

Experimental Example 2

Cytotoxicity of Mimosa Extracts

In order to confirm the cytotoxicity of mimosa extracts, 5 * 10 ⁵ cells / ml of EoL-1 cells (human eosinophilic leukemic cells) were treated with 10 μg / ml of Examples 1 to 5, and after 24 hours, MTT ( 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-2H-tetrazolium bromide) analysis was performed, and the results are shown in FIG. 4.

As shown in Figure 4, when the mimosa extract treatment, cell viability was not reduced compared to the control group, the mimosa extract did not show the toxicity to the cells at the concentration.

Experimental Example 3

Inhibitory Effects of Mimosa Extracts on Inflammatory Cytokines and Chemokines in EoL-1 Cells

Human eosinophils, like mast cells, produce a variety of cytokines and chemokines in acute inflammatory reactions such as asma (asthma), exacerbating the disease. In vitro experiments using human Eosinophil EoL-1 cells were performed.

24 hours of treatment with house dust mites (1 μg / ml) after pretreatment of 10 μg / ml of Examples 1 to 5 for 1 hour to 1 * 10 ⁶ cells / ml of EoL-1 cells (human eosinophilic leukemic cells) Afterwards, the amount of MCP-1 and IL-6 was measured in the supernatant using ELISA, and the results are shown in FIGS. 5 and 6.

5 and 6, each MCP-1 increased by mites

(FIG. 5; unit pg / mL) and IL-6 (FIG. 6; unit pg / mL) were confirmed to be inhibited by mimosa extract.

Cytokines, such as MCP-1 and IL-6, are secreted from various cells to induce the migration of inflammatory cells and play an important role in the regulation of inflammatory responses by being involved in activity. MCP-1 is produced in monocytes, fibroblasts, endothelial cells, and the like. In addition, in various inflammatory diseases such as asma, rheumatoid arthritis, and atherosclerosis, a large number of mononuclear cells and T cells are brought into the inflammatory site to worsen the inflammatory response. IL-6 is produced by T cells and macrophage activated in the immune response and increased IL-6 induces an inflammatory response.

Therefore, mimosa extracts according to the present invention could be confirmed to inhibit the secretion of cytokines and chemokines involved in the inflammatory response, indicating that it is effective in the treatment for allergic diseases.

Experimental Example 4

Anti-allergic Effect of Mimosa Extracts in Asthma-induced Mice Induced by Ovalbumin

Asthma-induced mice were used to observe the anti-allergic effect of mimosa extracts in in vivo experiments.

As an animal experiment to confirm the effects of mimosa extracts by inducing asthma disease, 10 mice with asthma disease-induced intraperitoneal injection of 20 μg per egg albumin at 2 week intervals were performed twice. After 1 week of infusion, 5% egg albumin solution was inhaled for 1 hour daily for 1 week.

Three weeks after the start of the experiment, the following tests were performed.

As a control group, the asthmatic non-induced mouse group (N) was not treated with egg albumin to induce asthma and did not receive mimosa extract.

Asthma-induced as a control group-Mimosa extract Untreated group (C) induced asthma as described above, but did not perform any drug treatment including mimosa extract.

Asthma-induced mice were further divided into mimosa extract group, dexamethasone oral group (Dex) 1 mg, and dexamethasone intraperitoneal group (Dex ip).

The mimosa extract-administered groups were subdivided into a group administered with 1 mg daily mimosa extract (Mp 1), a group administered 2.5 mg daily mimosa extract (Mp 2.5) and a group administered 5 mg daily mimosa extract (Mp 5).

Effects on white blood cells and eosinophils

Figure 7 shows the results of measuring the number of white blood cells present in the lung washing solution (BALF) of asthma-induced mice. As shown in FIG. 7, the number of leukocytes increased by 10 times in the asthma-induced group compared to the normal group, but it was confirmed that the mimosa extract treated group was significantly reduced.

Figure 8 shows the measurement results for eosinophils, the cells that mainly act on asthma in the white blood cells. As shown in Figure 8, the eosinophils increased in the asthma-induced group was confirmed to be greatly reduced by mimosa extract.

Impact on lung tissue

Lung tissues close to trachea were extracted from asthma-induced mice and fixed to prepare paraffin tissue blocks. Thereafter, tissue sections were prepared using a microtome, and then subjected to H & E staining (hematoxylin & eosin stain), and observed under a microscope. The results are shown in FIG. 9. As shown in FIG. 9, the number of cells infiltrated into the bronchus increased and the alveoli were narrowed in the asthma-induced group compared to the normal group, whereas in the mimosa extract-administered groups, the number of cells decreased and the alveolar morphology was similar to normal. Observation was possible.

Periodic acid-schiff staining was performed on the tissue sections in the same manner as in the H & E staining and observed under a microscope. The results are shown in FIG. 10. As shown in FIG. 10, it was observed that the secretion of mucus increased in the bronchus in the asthma-induced group compared to the normal group, and the mimosa extract-administered group was dependent on the concentration of the mimosa extract in comparison with the asthma-induced group. It can be seen that the number of decreases.

Impact on IL-5

The amount of cytokine IL-5 (interleukin-5) in the lung wash solution of asthma-induced mice was measured by ELISA, and the results are shown in FIG. 11. As shown in FIG. 11, the expression level of interleukin-5 increased in the asthma-induced group compared to the normal group was decreased in the mimosa extract-administered group, thereby confirming the inhibitory effect of interleukin-5 expression by the mimosa extract.

Impact on immunoglobulin E

Total immunoglobulin E (FIG. 11) and albumin specific immunoglobulin E antibodies (FIG. 12) in the lung wash solution of asthma-induced mice were measured using the ELISA method, and the results are shown in FIGS. 12 and 13. Asthma-induced group was increased compared to the normal group, the amount of total immunoglobulin E by the mimosa extract was reduced (Fig. 12), it was confirmed that the amount of albumin-specific immunoglobulin E (Fig. 13). In particular, the adverse effects on albumin-specific immunoglobulin E were large.

Effect on Serum Immunoglobulin E Levels

Total immunoglobulin E (FIG. 14) and albumin specific immunoglobulin E (FIG. 15) antibodies in the serum of asthma-induced mice were measured using the ELISA method, and the results are shown in FIGS. 14 and 15. Asthma-induced group was increased compared to the normal group, the total amount of immunoglobulin E by the mimosa extract was reduced (Fig. 14), it was confirmed that the amount of albumin-specific immunoglobulin E (Fig. 15). In particular, the adverse effects on albumin-specific immunoglobulin E were large.

Impact on GOT and GPT Levels

In experiments using asthma-induced mice, hepatotoxicity tests were performed to determine whether mimosa extracts were toxic to mice. Hepatotoxicity was typically determined by measuring increased levels of GOT and GPT, and the results are shown in FIGS. 16 and 17. As a result, it was confirmed that the GOT (FIG. 16) and GPT (FIG. 17) did not increase in the normal group, the asthma-induced mouse group, the mimosa extract administration group, and the dexamethasone administration group. This indicates that mimosa extract is not toxic in mice.

As a result of the synthesis of the above embodiments, the mimosa extract inhibits the stem cell factor-induced motility of the mast cells (HMC-1), inflammatory cytokines and chemokine MCPs in EoL-1 cells. -1, confirmed the inhibitory effects of the production of interleukin-6, and tested for cytotoxicity to determine whether it is possible to prepare a non-toxic or low-toxic pharmaceutical composition, the extract of the mimosa extract asthma disease-inducing mice By confirming the effects that the pharmaceutical composition comprising the extract of the mimosa as an active ingredient can be usefully used for atopic diseases and asma (asthma) diseases, etc., it is possible to prepare a non-toxic or low-toxic pharmaceutical composition, the mimosa Pharmaceutical compositions using the extract as an active ingredient may be useful for diseases such as atopy and asthma. The confirmed.

The present invention provides a pharmaceutical composition useful for the treatment of diseases such as atopy and asthma, and thus can be used in the pharmaceutical industry and the like.

1 is a view schematically illustrating a process for causing atopic dermatitis and asma histological lesions.

2 is a diagram schematically illustrating the interaction between cytokines and chemokines that cause atopic dermatitis and asma.

Figure 3 is a graph showing the inhibitory effect on the migration of mast cells of mimosa extract.

Figure 4 is a graph showing the cytotoxicity of mimosa extracts.

5 and 6 are graphs showing the inhibitory effect of mimosa extracts on inflammatory cytokines and chemokines in EoL-1 cells.

7 to 17 show the anti-allergic effect of mimosa extract in asthma-induced mice induced by Ovalbumin, and FIGS. 7 and 8 are graphs showing the effects on leukocytes and eosinophils. 10 are photographs showing the effects on lung tissue, FIG. 11 is a graph showing the effects on IL-5, FIGS. 12 and 13 are graphs showing the effects on immunoglobulin E, and FIGS. 14 and 15 are Graphs showing effects on serum immunoglobulin E, and FIGS. 16 and 17 show effects on GOT and GPT levels in the liver. Graphs.

Claims (4)

An ethanol extract, hexane fraction of the ethanol extract, ethyl acetate fraction of ethanol extract, butanol fraction of ethanol extract and water fraction of ethanol extract, extracts of atopic dermatitis and mimosa for asma improvement or treatment. delete Extracts of mimosa selected from the group consisting of ethanol extract, hexane fraction of the ethanol extract, ethyl acetate fraction of ethanol extract, butanol fraction of ethanol extract, and water fraction of ethanol extract as active ingredients and pharmaceutically acceptable carriers Atopic dermatitis and asma improvement or treatment pharmaceutical composition comprising a. delete

Images